Table 1. Description of 54 cases of Hcd infection in the RoC.
| Age/ Sex | No. of cases | Years | Origin areas | Occupation | HIV infection | Site of infection | Disseminated form | Treatment | Posology | Outcome | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -/M | 1 | 1954 | Urban | NS | NT | Brain, Skin (Subcutaneous) | Yes | Terramycine, pentamidine | 1.5 g/day for 1 month | Good general condition. Chronic evolution of the disease |
Audebaud et al. [10] |
| 15/F | 1 | 1970 | Rural | NS | NT | Skin | NS | NS | NS | NS | Destombes et al. [12] |
| NS | 1 | 1967 | NS | NS | NT | Skin | NS | NS | NS | NS | Renoirte et al. [13] |
| 44/M | 1 | 1981 | Rural | Farmer | NT | Skin | No | AmB | 0.6 to 1 mg/kg to 1 mg/kg in 1 day over 2. Given as an infusion | Favorable outcome | Carme et al. [14] |
| 6/F | 1 | 1982 | Rural | Pupil | NT | Skin | No | ||||
| 36/M | 1 | 1983 | Rural | Farmer | NT | Skin, mucosa | No | ||||
| 13/F | 1 | 1983 | Rural | Pupil | NT | Mucosa, Bone | No | ||||
| 25/M | 1 | 1983 | Rural | Unemployed | NT | Skin | No | ||||
| 45/M | 1 | 1984 | Rural | NS | NT | Skin | No | ||||
| 11/M | 1 | 1984 | Urban | NS | NT | Skin, Bone | Yes | AmB | 1.6 g/24 h every 2 days | Favorable outcome | Griffet et al. [15] |
| 26/F | 1 | 1985 | NS | Unemployed | NT | Skin | No | AmB | 0.6 to 1 mg/kg to 1 mg/kg in 1 day over 2. Given as an infusion | Favorable clinical response | Carme et al. [14] |
| 27/M | 1 | 1986 | NS | Farmer | Negative | Skin | No | ||||
| 2/F | 1 | 1987 | NS | - | NT | Skin, Bone, Eye | Yes | AmB | |||
| 13/M | 1 | 1988 | NS | Pupil | NT | Skin, Bone, Shoulder | Yes | AmB | |||
| 17/M | 1 | 1989 | NS | Pupil | Negative | Skin | No | AmB | |||
| 17/M | 1 | 1989 | NS | Pupil | Negative | Skin, mucosa | No | ||||
| 26/M | 1 | 1990 | NS | Student | Positive | Skin | Yes | AmB KETO |
0.6 to 1 mg/kg to 1 mg/kg in 1 day over 2. Given as an infusion | Death | |
| 50/M | 1 | 1990 | NS | Farmer | Negative | Skin | Yes | AmB KETO |
0.6 to 1 mg/kg to 1 mg/kg in 1 day over 2. Given as an infusion | Death | |
| 13/M | 1 | 1991 | Rural | NS | NT | Bone | Yes | AmB, Surgery | 1.50 g Given as an infusion |
Favorable clinical response at months 3. No relapse at 1 year |
Moyikoua et al. [16] |
| NS | 11 | 1990 | NS | NS | Positive | NS | Yes | NS | NS | NS | Carme et al. [11] |
| 26/M | 1 | 1992 | NS | Student | Positive | Skin (cutaneous and subcutaneous) | Yes | NS | NS | Death | Carme et al. [17] |
| 4/M | 1 | 1995 | Urban | - | Negative | Lung, Skin, Bone | Yes | KETO AmB |
1/2 tablets/day 0.5 mg/kg × 2 days |
Favorable clinical response | Chandenier et al. [18] |
| 20/F | 1 | 1995 | Rural | NS | Positive | Skin | Yes | AmB ITRA |
1 mg/kg × 2 days 300 mg/days |
Death | |
| 44/M | 1 | 1995 | Urban | Driver | Positive | Skin | Yes | KETO AmB |
600 mg/days for 2 months and half. 1 mg/kg, 3 days/week. Given as an infusion |
Death | |
| 45/M | 1 | 1995 | Urban | NS | NT | Skin | - | NS | NS | Death | |
| 41/M | 1 | 1995 | Urban | NS | Positive | Skin | Yes | AmB | 1mg/kg/week | NS | |
| 32/M | 1 | 1995 | Urban | Nurse | Positive | Skin, Bone | Yes | AmB | 1mg/kg/week | NS | |
| NS | 1 | 2004 | Urban | NS | Positive | NS | Yes | NS | NS | Ondzotto et al. [19] | |
| 17/M | 1 | 2004 | Urban | NS | Negative | Skin, Bone | Yes | AmB | 0.25 mg/kg. Given as intravenous infusion. Increased by 5mg/days to a maximum of 1 mg/kg/day |
Favorable clinical response at months 11 | N’Golet et al. [20] |
| 33/F | 1 | 2006 | Urban | NS | Positive | Skin | Yes | Liposomal AmB, ITRA |
3 mg/kg per day 400 mg/day |
Death | Therby et al. [21] |
| 60/F | 1 | 2006 | Rural | Farmer | Negative | Skin, Bone | Yes | AmB, Terbinafine |
1mgkg/day for 30 days 250 mg/day |
Favorable clinical response at months 8 | Ngatse-Oko et al. [22] |
| 41/M | 1 | 2006 | Urban | NS | Positive | Skin | Yes | AmB ITRA |
NS | Favorable outcome. No relapse at 6.5 years. |
Breton et al. [23] |
| 15/M | 1 | 2010 | Urban | NS | Negative | Skin, Lung | Yes | None | - | Death | Okoko et al. [24] |
| 1/M | 1 | 2011 | Urban | - | Negative | Eye | No | AmB | 0.5 mg/kg Given as intravenous |
Favorable outcome at months 6 | Eboulabeka et al. [25] |
| 9/F | 1 | 2017 | Urban | NS | Negative | Skin | Yes | KETO | 200 mg × 2 /days | Insidious outcome at month 1. Death at months 3 |
Babela et al [26] |
| 3/M | 1 | 2017 | Urban | - | Negative | Skin | Yes | ITRA | 200 mg/day in per os | Insidious outcome at day 21. Death at months 2 |
|
| 4/M | 1 | 2017 | Urban | - | Negative | Bone | Yes | ITRA | 200 mg/day in per os | Insidious outcome at day 28. Death at months 3 |
|
| 7/F | 1 | 2014 | Urban | NS | Negative | Skin, Bone | Yes | Surgery, ITRA | 400 mg × 2/days. Given orally | Favorable clinical response at months 3 | Paugam et al. [27] |
| 30/F | 1 | 2019 | Urban | Unemployed | Negative | Skin | No | Surgery, ITRA | 800 mg/days for 12 weeks | Favorable outcome | Boukassa et al. [28] |
| 29/F | 1 | 2019 | Urban | Secretary | Negative | Skin | No | Surgery, ITRA | 800 mg/days for 12 weeks | ||
| 60/M | 1 | 2019 | Urban | Administrator | Negative | Skin, lung | Yes | Surgery, ITRA | 800 mg/days for 12 weeks | Death | |
| 52/M | 1 | 2019 | Urban | Construction worker | Negative | Skin, lung | Yes | Surgery, ITRA | 800 mg/days for 12 weeks | Death | |
| 34/M | 1 | 2019 | Urban | Sawyer | Negative | Skin, lung | Yes | None | - | Death | |
| 30/F | 1 | 2018 | Urban | NS | Negative | Skin, bone | Yes | ITRA | 800 mg/days for 12 weeks | Favorable outcome | Boukassa et al. [29] |
AmB, Amphotericin B; ITRA, Itraconazole; KETO, Ketoconazole; NS, not specified; NT, not tested.
Urban referred to the capital city, Brazzaville.